IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Creative Planning

Creative Planning trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,822 shares of the company’s stock after selling 303 shares during the quarter. Creative Planning’s holdings in IDEXX Laboratories were worth $11,606,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC increased its stake in IDEXX Laboratories by 86.1% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 2,538 shares of the company’s stock worth $1,409,000 after buying an additional 1,174 shares during the period. The Manufacturers Life Insurance Company grew its stake in IDEXX Laboratories by 3.9% during the 4th quarter. The Manufacturers Life Insurance Company now owns 90,433 shares of the company’s stock worth $50,195,000 after purchasing an additional 3,436 shares in the last quarter. Rafferty Asset Management LLC increased its holdings in IDEXX Laboratories by 4.3% during the 4th quarter. Rafferty Asset Management LLC now owns 29,357 shares of the company’s stock worth $16,295,000 after purchasing an additional 1,215 shares during the period. Eisler Capital UK Ltd. purchased a new stake in IDEXX Laboratories during the 4th quarter worth about $686,000. Finally, Lake Street Advisors Group LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $517,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $495.42 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The stock has a market cap of $40.92 billion, a PE ratio of 47.96, a price-to-earnings-growth ratio of 4.32 and a beta of 1.33. The firm has a fifty day moving average price of $487.24 and a 200 day moving average price of $496.69.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the company earned $2.67 earnings per share. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on IDXX shares. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Piper Sandler reduced their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Finally, BTIG Research started coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $582.25.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.